CSN5-IN-2 (Compound 31) is a CSN5 inhibitor with an IC50 of 0.36 µM. It increases Cullin 1 neddylation levels in cancer cells and downregulates the expression of RAD51 and PD-L1. CSN5-IN-2 exhibits antitumor activity, which is enhanced when used in combination with Talazoparib.
Target:
PD-1/PD-L1|||DNA/RNA Synthesis
* VAT and and shipping costs not included. Errors and price changes excepted
